2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)thiophene CAS 1030825-20-7 Purity ≥98.0% (HPLC)

Short Description:

2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)thiophene

CAS: 1030825-20-7

Appearance: White or Off-White Powder

Purity: ≥98.0% (HPLC)

Intermediate of API (CAS: 842133-18-0) in the treatment of Type 2 Diabetes Mellitus

Inquiry: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer Supply Related Intermediates:
4-Fluorophenylboronic Acid CAS: 1765-93-1
2-(4-Fluorophenyl)thiophene CAS: 58861-48-6
2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone CAS: 32384-65-9
5-Iodo-2-Methylbenzoic Acid CAS 54811-38-0
2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)thiophene CAS: 1030825-20-7
2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene CAS: 898566-17-1
CAS: 842133-18-0
CAS: 928672-86-0

Chemical Properties:

Chemical Name	2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)thiophene
CAS Number	1030825-20-7
CAT Number	RF-PI234
Stock Status	In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula	C18H14BrFS
Molecular Weight	361.27
Melting Point	103℃
Density	1.388
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White or Off-White Powder
Purity / Analysis Method	≥98.0% (HPLC)
Loss on Drying	≤1.00%
Residue on ignition	≤0.50%
Heavy Metals	≤20ppm
Test Standard	Enterprise Standard
Usage	Intermediate of API (CAS: 842133-18-0)

Package & Storage:

Package: Bottle, Aluminum foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light & moisture

Advantages:

FAQ:

Application:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)thiophene (CAS: 1030825-20-7) with high quality. It is an intermediate typically in the synthesis of API (CAS: 461432-26-8). API (CAS: 461432-26-8) is a new antidiabetic drug jointly developed by Bristol-Myers Squibb and AstraZeneca, being approved by the European Medicines Agency (EMA) on November 12, 2012. It is also the first approved SGLT2 inhibitor for the treatment of type II diabetes, being an important option in the treatment of diabetes, and is used to improve glycemic control as an adjunct to dietary and exercise for adults with type II diabetes.